Welcome to our dedicated page for Galapagos NV news (Ticker: GLPG), a resource for investors and traders seeking the latest updates and insights on Galapagos NV stock.
Galapagos NV (GLPG) is a clinical-stage biotechnology company dedicated to discovering and developing small molecule medicines with innovative modes of action. With operations in Europe and the USA, the company focuses on addressing diseases with high unmet medical needs by leveraging its extensive R&D capabilities. The portfolio of Galapagos comprises programs from discovery to commercialization in areas such as immunology and oncology.
Galapagos' first medicine targeting rheumatoid arthritis and ulcerative colitis is already available in Europe and Japan. The company also maintains a significant revenue stream from the United States.
Recent achievements include a strategic manufacturing agreement with Landmark Bio to produce clinical trial batches of chimeric antigen receptor (CAR) T-cell therapies. This partnership aims to enhance Galapagos' decentralized CAR-T manufacturing model, allowing for quicker administration of treatments to patients. Another notable collaboration is with BridGene Biosciences, focusing on discovering novel small molecule drug candidates for oncology using BridGene's chemoproteomics platform, IMTAC™.
Furthermore, Galapagos has entered a clinical collaboration with Adaptimmune Therapeutics to develop next-generation TCR T-cell therapies targeting MAGE-A4 for head and neck cancer. This agreement leverages Galapagos' decentralized cell manufacturing platform, which promises rapid access to potentially transformative treatments for patients.
Committed to improving lives worldwide, Galapagos combines compelling science, advanced technology, and strategic partnerships to create a robust pipeline of best-in-class small molecules, CAR-T therapies, and biologics. The company is driven by its mission to challenge the status quo and deliver exceptional outcomes for patients, employees, and shareholders alike.
Excellos Inc., a cell therapy CDMO member of Blood Centers of America (BCA), has been selected to manufacture Galapagos' CAR-T cell therapy candidate, GLPG5101, for its FDA-cleared ATALANTA-1 clinical study in patients with relapsed/refractory non-Hodgkin lymphoma in the U.S. Excellos will provide end-to-end manufacturing at its new facility in San Diego, CA, using Galapagos' innovative, decentralized manufacturing platform.
This platform aims to address limitations in CAR-T cell therapy production, offering greater speed and scalability with a median vein-to-vein time of seven days. The collaboration is part of a strategic agreement between Galapagos' U.S. entity and BCA, which will provide decentralized manufacturing services for Galapagos' CAR-T cell therapy candidates across the U.S., close to cancer treatment centers.
BridGene Biosciences has expanded its strategic collaboration with Galapagos NV (NASDAQ: GLPG) to develop a selective oral SMARCA2 PROTAC for precision oncology. The collaboration, which builds on their January 2024 partnership, combines BridGene's PROTAC discovery engine with Galapagos' expertise in selective ATPase small molecules. BridGene is eligible to receive up to $159 million in total payments, including upfront and milestone payments, as well as tiered royalties on net sales. Galapagos will have exclusive rights for further development and commercialization of the preclinical candidate.
This expanded partnership aims to advance drug discovery for challenging oncology targets, leveraging the strengths of both companies to develop precision medicines for cancer patients with critical unmet needs. The collaboration underscores the importance of strategic alliances in advancing drug development efforts and validates BridGene's innovative approach in small molecule drug discovery for hard-to-drug targets.
Adaptimmune and Galapagos have entered a clinical collaboration to evaluate Adaptimmune's TCR T-cell therapy candidate, uza-cel, in head & neck cancer. The trial aims to leverage Galapagos' decentralized manufacturing platform to improve efficacy and durability. Initial trials showed an 80% response rate with partial responses in four out of five patients. Adaptimmune will receive $70M upfront, $30M in R&D funding, and potentially up to $465M in milestone payments, with additional tiered royalties. Galapagos has an option to license uza-cel for global development and commercialization.
Scipher Medicine announced that Galapagos (GLPG) has exercised its option to in-license novel drug targets for inflammatory bowel disease (IBD), following preclinical validation work. This collaboration will trigger a milestone payment to Scipher and allow them to receive additional payments based on future regulatory and sales milestones. The partnership is aimed at developing therapies for unmet needs in IBD using Scipher's Spectra™ platform, which leverages extensive molecular data to enhance drug response rates.
Galapagos NV and Gilead Sciences have announced the halt of the ISABELA Phase 3 clinical studies for ziritaxestat, an investigational autotaxin inhibitor for idiopathic pulmonary fibrosis (IPF). This decision follows the Independent Data Monitoring Committee's review, which indicated that the benefit-risk profile of ziritaxestat no longer supports ongoing trials. The ISABELA program aimed to enroll 1,500 patients, but all trials, including a Phase 2a extension, will be discontinued. Both companies expressed disappointment but remain committed to advancing IPF research.
Galapagos NV (GLPG) announces the completion of Selvita S.A.'s acquisition of Fidelta for €31.2M. This strategic move nearly doubles Selvita's revenues, enhancing its drug discovery services. Fidelta, located in Croatia, employs 181 scientists and has a strong history in inflammation and fibrosis research. The acquisition strengthens Selvita’s position in the European contract research market and allows Fidelta to continue providing services to Galapagos for five years, ensuring ongoing collaboration.
On November 23, 2020, Galapagos NV (GLPG) announced the acquisition of Fidelta d.o.o. by Selvita S.A. for an enterprise value of €31.2M, to be paid in cash. This acquisition is poised to enhance Selvita's position as a leading preclinical contract research organization in Europe, almost doubling its revenues. Fidelta, currently providing drug discovery services, will continue its operations for Galapagos for the next five years. The deal is expected to close on January 4, 2021, and will significantly expand Selvita's integrated drug discovery services.
FAQ
What is the current stock price of Galapagos NV (GLPG)?
What is the market cap of Galapagos NV (GLPG)?
What does Galapagos NV specialize in?
Where does Galapagos NV operate?
What are some recent collaborations of Galapagos NV?
What is the focus of Galapagos NV's clinical collaboration with Adaptimmune Therapeutics?
What kind of diseases does Galapagos NV target?
What is Galapagos NV's approach to CAR-T cell therapies?
What products has Galapagos NV commercialized?
How does Galapagos NV generate revenue?
What is the primary goal of Galapagos NV?
Where can I find additional information about Galapagos NV?
